[Level of interleukin-6 (IL-6), soluble interleukin-6 receptors (sIL-6R) and tumor necrosis factor alpha (TNF-alpha) in untreated and progressing multiple myeloma].
36 MM pts in advanced stage, 17 recently diagnozed (group I) and 19 in the progression of the disease (group II) were examined. 10 pts of group I and 12 of group II had renal failure. Levels of II-6, sII-6R and TNF-alpha were measured in pts sera before cytostatic therapy or plasma exchange (PE) and after 4-week therapy. The plasma concentration of II-6, sIl-6R and TNF-alpha before chemotherapy were 47-426 pg/ml, 33-III ng/ml and 19-350 pg/ml respectively and were significantly higher than in healthy control (group III) but no significant changes were observed between group I and group II. Patients with renal failure showed significantly higher II-6 and sIl-6R plasma levels than those with normal renal function. After 4 weeks of chemotherapy plasma concentration of the examined parameters decreased only in those pts of both groups, who later, after 6 mos disclosed a therapeutic response. Median survival time (m-ST) of recently diagnosed MM pts was 38 mos and in those with progression of underlying disease-43 mos. M-ST of 5 pts whose levels of Il-6 > 150 pg/ml, sIl-6R > 55 ng/ml and TNF-alpha-150 pg/ml was only 18 mos, but when only one of them was so much elevated it attained 55 mos. (p = 0.01).
Usnarska-Zubkiewicz
L
L
Katedra i Klinika Hematologii i Chorób Rozrostowych AM we Wrocławiu.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D011241:Prednisone / Q000008:administration & dosage; D018123:Receptors, Interleukin / Q000097:blood*; D019947:Receptors, Interleukin-6; D011993:Recombinant Fusion Proteins / Q000097:blood; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D014750:Vincristine / Q000008:administration & dosage
D015850:Interleukin-6; D018123:Receptors, Interleukin; D019947:Receptors, Interleukin-6; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; C104543:interleukin 6-interleukin 6 receptor fusion protein, recombinant; D014750:Vincristine; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone; D008775:Methylprednisolone